Radiobiological characterisation and therapy monitoring of oligo- compared to polymetastatic breast cancer
Not Applicable
Suspended
- Conditions
- C50Malignant neoplasm of breast
- Registration Number
- DRKS00031591
- Lead Sponsor
- Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Hamburg-Eppendorf
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Suspended
- Sex
- Female
- Target Recruitment
- 50
Inclusion Criteria
Metastatic breast cancer patient undergoing radiotherapy (RT) of macroscopic tumour to at least one metastatic site
- > 18 years
- Female
- Ability to report patient-reported outcomes in case of palliative radiotherapy
- Patient gave informed consent
Exclusion Criteria
- Patients receiving only RT of a tumour bed/resection cavity with no macroscopic lesion
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Characterisation of circulating tumor cells and peripheral blood lymphocytes in patients with oligo- and polymetastatic disease. Peripheral blood will be examined at the first and last fraction of radiotherapy as well as the first follow-up at 6 to 8 after treatment.
- Secondary Outcome Measures
Name Time Method ocal control and symptomatic response of treated metastases as well as time to further distant metastasis in dependence of radiobiological factors.